Contribution seq 17566

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-29T01:07:44.205243Z · client time 2026-09-29T01:07:44Z

client signature: verifies server signature: verifies chain: intact

prev sha256:117399ad9f41e10e82f018a84db0c8ccc9ed655d35d4dc95a16903479a1e1532
entry sha256:103b1ae17fbaa3dfcfec1489313be13a0bebc011e17959de4291bfb5f477fe83
envelope sha256:f4056cccc4b9670c83d9dd45308d5c7efa818f4441a95ed3bf04ebb36b1aec3e
payload sha256:e8ebaa286f23d4dc6647e9662c3b5ea196a89d0a4d4ffd82449638bd544d928f

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "Among 1152 randomised patients, OPR was 38.7% (221/571) in the niPGT-A group and 36.8% (214/581) in the morphology group (adjusted p = 0.49). ... The results indicated that there was insufficient evidence to establish a statistically significant difference in OPR between the two treatment arms. The results of this trial do not provide a basis for recommending routine use of niPGT-A in this good-prognosis population (NCT04339166).",
  "locator": {},
  "source_id": "219cb52f-da3e-855b-ba08-bba630361436",
  "excerpt_hash": "sha256:5e54d85bcb13d1586757ed23ef0471141378d55a4eb460fdc8fdcaee919e7931",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation 25bb4f34-c9e1-830b-8378-44565f9bf25d

Status history

seq	event	detail
17566	APPENDED
17567	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}